These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner. Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673 [TBL] [Abstract][Full Text] [Related]
3. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Haller J; Bakos N; Szirmay M; Ledent C; Freund TF Eur J Neurosci; 2002 Oct; 16(7):1395-8. PubMed ID: 12405999 [TBL] [Abstract][Full Text] [Related]
4. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice. Rodgers RJ; Evans PM; Murphy A Behav Pharmacol; 2005 Sep; 16(5-6):405-13. PubMed ID: 16148445 [TBL] [Abstract][Full Text] [Related]
5. Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention. Bowers ME; Ressler KJ Neuropsychopharmacology; 2015 Feb; 40(3):688-700. PubMed ID: 25176168 [TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptor type 1 receptors on GABAergic vs. glutamatergic neurons differentially gate sex-dependent social interest in mice. Terzian AL; Micale V; Wotjak CT Eur J Neurosci; 2014 Jul; 40(1):2293-8. PubMed ID: 24698342 [TBL] [Abstract][Full Text] [Related]
7. Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Thiemann G; Watt CA; Ledent C; Molleman A; Hasenöhrl RU Behav Brain Res; 2009 Jun; 200(1):60-7. PubMed ID: 19162082 [TBL] [Abstract][Full Text] [Related]
8. Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze. Huang P; Liu-Chen LY; Kirby LG Neurosci Lett; 2010 May; 475(3):165-8. PubMed ID: 20363293 [TBL] [Abstract][Full Text] [Related]
9. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. Gueye AB; Pryslawsky Y; Trigo JM; Poulia N; Delis F; Antoniou K; Loureiro M; Laviolette SR; Vemuri K; Makriyannis A; Le Foll B Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27493155 [TBL] [Abstract][Full Text] [Related]
10. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Griebel G; Stemmelin J; Scatton B Biol Psychiatry; 2005 Feb; 57(3):261-7. PubMed ID: 15691527 [TBL] [Abstract][Full Text] [Related]
11. Effects of rimonabant on the development of single dose-induced behavioral sensitization to ethanol, morphine and cocaine in mice. Marinho EA; Oliveira-Lima AJ; Santos R; Hollais AW; Baldaia MA; Wuo-Silva R; Yokoyama TS; Takatsu-Coleman AL; Patti CL; Longo BM; Berro LF; Frussa-Filho R Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():22-31. PubMed ID: 25496830 [TBL] [Abstract][Full Text] [Related]
12. Resting State Brain Networks under Inverse Agonist versus Complete Knockout of the Cannabinoid Receptor 1. Li H; Ye Q; Wang D; Shi B; Xu W; Zhang S; Han X; Zhang XY; Thompson GJ ACS Chem Neurosci; 2024 Apr; 15(8):1669-1683. PubMed ID: 38575140 [TBL] [Abstract][Full Text] [Related]
13. Blockade of Serotonin 2C Receptors with SB-242084 Moderates Reduced Locomotor Activity and Rearing by Cannabinoid 1 Receptor Antagonist AM-251. Bogáthy E; Kostyalik D; Petschner P; Vas S; Bagdy G Pharmacology; 2019; 103(3-4):151-158. PubMed ID: 30673678 [TBL] [Abstract][Full Text] [Related]
14. Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior. Schneider M; Kasanetz F; Lynch DL; Friemel CM; Lassalle O; Hurst DP; Steindel F; Monory K; Schäfer C; Miederer I; Leweke FM; Schreckenberger M; Lutz B; Reggio PH; Manzoni OJ; Spanagel R J Neurosci; 2015 Oct; 35(41):13975-88. PubMed ID: 26468198 [TBL] [Abstract][Full Text] [Related]
15. The genetic versus pharmacological invalidation of the cannabinoid CB(1) receptor results in differential effects on 'non-associative' memory and forebrain monoamine concentrations in mice. Thiemann G; Fletcher BC; Ledent C; Molleman A; Hasenöhrl RU Neurobiol Learn Mem; 2007 Nov; 88(4):416-23. PubMed ID: 17884611 [TBL] [Abstract][Full Text] [Related]
16. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Rodgers RJ; Haller J; Halasz J; Mikics E Eur J Neurosci; 2003 Mar; 17(6):1279-86. PubMed ID: 12670316 [TBL] [Abstract][Full Text] [Related]
17. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Moreira FA; Kaiser N; Monory K; Lutz B Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120 [TBL] [Abstract][Full Text] [Related]
18. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764 [TBL] [Abstract][Full Text] [Related]
19. Bladder function in a cannabinoid receptor type 1 knockout mouse. Füllhase C; Campeau L; Sibaev A; Storr M; Hennenberg M; Gratzke C; Stief C; Hedlund P; Andersson KE BJU Int; 2014 Jan; 113(1):144-51. PubMed ID: 24053792 [TBL] [Abstract][Full Text] [Related]
20. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Micale V; Cristino L; Tamburella A; Petrosino S; Leggio GM; Drago F; Di Marzo V Neuropsychopharmacology; 2009 Feb; 34(3):593-606. PubMed ID: 18580871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]